Roche inks $2.3 billion deal with Nurix for cancer drug development

Roche agreed to pay Nurix Therapeutics as much as $2.3 billion for rights to bexobrutideg, a blood-cancer drug that has not yet reached late-stage testing. The deal puts $700 million upfront on the table for an oral Bruton’s tyrosine kinase degrader that Roche plans to push into phase III trials in summer 2026 for second-line chronic lymphocytic leukemia, underscoring how aggressively drugmakers are chasing oncology assets that could stand out from today’s standard treatments.

The attraction is not just the size of the market, but the mechanism. Bexobrutideg, also known as NX-5948, is designed to eliminate the BTK protein rather than simply inhibit it, a distinction that Roche and Nurix say could improve efficacy and tolerability and help overcome resistance to existing BTK inhibitors. Roche’s chief medical officer, Levi Garraway, said the drug could be a “major leap forward” for complex blood cancers and other diseases. The companies also said the program could eventually extend beyond malignant hematology into immunology and neurology, including chronic spontaneous urticaria and multiple sclerosis.

The financial structure shows how much confidence Roche is putting behind the platform. Roche will fund 60% of development costs and Nurix 40%, while the companies will split profits and losses equally in the United States if the drug reaches the market there. Roche will commercialize the drug outside the United States and pay Nurix royalties. The deal is expected to close in the third quarter of 2026, turning the agreement into a near-term corporate event as well as a scientific bet.

That bet lands in a crowded and commercially important corner of oncology. Roche said the broader B-cell malignancy market is projected to reach $41 billion by 2031, with BTK inhibitors still expected to lead the class at about $19 billion. Roche also projected that the CLL market will rise from $12 billion in 2024 to $16 billion by 2035. Fierce Biotech said the drug is set to meet Eli Lilly’s Jaypirca in phase III, highlighting how BTK degradation is emerging as the next competitive front in a field where many patients eventually stop responding to current drugs.

The scale of the payment, paired with the still-early stage of development, captures the gap between financial promise and patient reality. Roche is buying time, access and optionality in a category that may redefine blood-cancer treatment, but the key readout will come years from now, after trials, safety work and regulatory review. For patients with resistant CLL, the promise is meaningful. For investors and competitors, the message is clearer: the next wave of cancer drug development is already being priced in.